Tabimorelin
Also known as: Ipamorelin analog (non-peptide), JMV-1843, NN703, Tabimorelin, Tabimorelin hydrate
Source Tabimorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tabimorelin is a synthetic peptide GH secretagogue investigated for treatment of growth hormone deficiency and for anabolic effects in adults.
Mechanism of Action
Agonist of the growth hormone secretagogue receptor (GHSR1a), stimulating pulsatile growth hormone release from the pituitary.
Routes of Administration
Goals & Uses
- Increase lean body massMusculoskeletalModerate
- Diagnostic testing for GH deficiencyDiagnosticsModerate
- Growth hormone deficiency (GHD) treatmentEndocrinologyModerate
- Growth hormone deficiencyEndocrineModerate
- IGF-1 elevationMetabolic / HormonalModerate
- Body composition improvementMetabolicLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Hypersensitivity to tabimorelinAllergy/ImmunologyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
- Proliferative or severe non-proliferative diabetic retinopathyOphthalmologyHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicCommonAbnormally high blood glucose
- Injection site painLocalCommonPain at the injection site
- Elevated blood glucose / insulin resistanceMetabolicUncommon
- Edema / fluid retentionMetabolicUncommon
- Increased appetite / hungerGastrointestinal / MetabolicCommon
- Cortisol elevationEndocrinologyUncommon
- Arthralgia / myalgiaMusculoskeletalUncommon
Drug Interactions
- InsulinLowMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Insulin / antidiabetic agentsModerate
- Somatostatin analogues (e.g., octreotide)High
Population Constraints
- Pediatric patientsAgeRelative
- Pediatric patients < 2 yearsAgeRelative
- Patients with diabetes mellitusMetabolicRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveAbsolute
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionInvestigationalInvestigational medicinal product; no EMA approval.
- United StatesInvestigationalPhase II clinical trials; not FDA approved.
- United KingdomInvestigationalClinical trial use only; not licensed.
Never received marketing approval; development discontinued after Phase II trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Tabimorelin?
Tabimorelin is a synthetic peptide GH secretagogue investigated for treatment of growth hormone deficiency and for anabolic effects in adults.
What is Tabimorelin used for?
Tabimorelin is educationally associated with: Increase lean body mass, Diagnostic testing for GH deficiency, Growth hormone deficiency (GHD) treatment, Growth hormone deficiency, IGF-1 elevation, Body composition improvement. Educational only — not medical advice.
How is Tabimorelin administered?
Recorded routes of administration: Intravenous, Oral, Subcutaneous.
What are the potential side effects of Tabimorelin?
Reported adverse effects include: Edema, Hyperglycemia, Injection site pain, Elevated blood glucose / insulin resistance, Edema / fluid retention, Increased appetite / hunger, Cortisol elevation, Arthralgia / myalgia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Tabimorelin?
Recorded contraindications: Active malignancy, Hypersensitivity to tabimorelin, Pregnancy, Uncontrolled Diabetes Mellitus, Proliferative or severe non-proliferative diabetic retinopathy. Consult a qualified clinician before use.